Result:Poor· Market: Crashed
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 9.00 | 21.0% | 17.1% |
| Total Income | 9.48 | 17.4% | 13.4% |
| Expenditure | 9.63 | 10.9% | 12.6% |
| PBT | -0.15 | 172.7% | 109.6% |
| Net Profit | -0.18 | 276.3% | 309.4% |
| OPM | -5.48% | 8.00pp | 5.29pp |
| NPM | -1.88% | 2.76pp | 1.48pp |
| EPS | 0.23 | 76.9% | 283.3% |
Standalone revenue fell 17.1% YoY and the company swung to a wider net loss (-0.18cr vs -0.04cr), a clear deterioration in the core pharma business with no offsetting one-off.
Informational and educational content only. Not investment advice.